Eli Lilly Signs $2.75 Billion AI Drug Development Deal with Insilico Medicine

Eli Lilly, a US pharmaceutical giant, has signed a $2.75 billion partnership with Insilico Medicine, a Hong Kong-listed AI drug developer, in one of the largest artificial intelligence-pharmaceutical deals to date. The agreement focuses on AI-driven drug development, leveraging Insilico Medicine's artificial intelligence technology platform to accelerate pharmaceutical discovery and development processes. The deal represents a significant bet by Eli Lilly on AI's potential to transform drug discovery and marks a major milestone for Insilico Medicine's commercial validation in the pharmaceutical industry.

Eli Lilly's $2.75 Billion AI Drug Development Partnership

• ▪Eli Lilly is a US pharmaceutical giant
• ▪Eli Lilly signed a $2.75 billion deal with Insilico Medicine for AI-driven drug development

Insilico Medicine's AI-Driven Drug Discovery Platform

• ▪Insilico Medicine develops drugs using artificial intelligence technology
• ▪Insilico Medicine is listed on the Hong Kong stock exchange

Perspective of Insilico Medicine

• ▪The $2.75 billion Eli Lilly partnership represents one of the largest AI-pharma deals to date